Teva To Expand Presence In India
This article was originally published in PharmAsia News
Executive Summary
LUCKNOW, UTTAR PRADESH, INDIA - Israeli pharmaceutical company Teva Pharmaceutical will invest more than $1 billion in India over the next two years to establish greenfield manufacturing facilities and acquire Indian drug companies, said a Jan. 10 report in the local newspaper Business Standard.
You may also be interested in...
U.S. Court Dismisses Teva’s Patent Infringement Plea Against Dr Reddy’s Carvedilol; Dr Reddy’s May Launch Drug Soon
MUMBAI - Dr Reddy's Labs may be able to sell generic versions of GlaxoSmithKline's hypertension drug Coreg (carvedilol) in the U.S. after it settled a case against Israeli drug maker Teva for four patents of the drug
U.S. Court Dismisses Teva’s Patent Infringement Plea Against Dr Reddy’s Carvedilol; Dr Reddy’s May Launch Drug Soon
MUMBAI - Dr Reddy's Labs may be able to sell generic versions of GlaxoSmithKline's hypertension drug Coreg (carvedilol) in the U.S. after it settled a case against Israeli drug maker Teva for four patents of the drug
Dr Reddy’s Earnings Plunge On German Unit Charge, Increased Generic Competition
NEW DELHI - Dr Reddy's Laboratories, India's second-biggest drugmaker, said third quarter earnings and revenues plunged on lower-than-expected earnings in Germany and increased competition as it changes its mix of generic drug products